A Phase 1B Dose-escalation Study of TRC105 in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma
Sponsors and Collaborators
Tracon Pharmaceuticals Inc.
Next post in Renal Cell Carcinoma Clinical Trials
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
Want to read more?
Please login or register first to view this content.